Pre-injection of magnesium sulfate enhances the efficacy of ibutilide for the conversion of typical but not of atypical persistent atrial flutter

International Journal of Cardiology

Volumn 141, Issue 3, 2010, Pages 260-265

  Steinwender, Clemens ^a   Hönig, Simon ^a   Kypta, Alexander ^a   Kammler, Jürgen ^a   Schmitt, Barbara ^a   Leisch, Franz ^a   Hofmann, Robert ^a  

^a KEPLER UNIVERSITY HOSPITAL   (Austria)

Author keywords

Atrial flutter; Conversion rate; Ibutilide; Magnesium

Indexed keywords

IBUTILIDE FUMARATE; MAGNESIUM SULFATE; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEART ATRIUM FLUTTER; HEART RHYTHM; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL;

AGED; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; ATRIAL FLUTTER; DRUG SYNERGISM; ELECTROCARDIOGRAM PATTERN; FEMALE; HEART CONDUCTION SYSTEM; HUMANS; INJECTIONS, INTRAVENOUS; MAGNESIUM SULFATE; MALE; MIDDLE AGED; PLACEBO EFFECT; PROSPECTIVE STUDIES; SULFONAMIDES; TREATMENT OUTCOME;

EID: 77952742932     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2008.12.012     Document Type: Article

References (27)

1. Ellenbogen K.A., et al., For the Ibutilide Investigators. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study. J Am Coll Cardiol 28 (1996) 130-136
2. Stambler B.S., Wood M.A., Ellenbogen K.A., Perry K.T., Wakefield L.K., and VanderLugt J.T. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation 94 (1996) 1613-1621
3. Ellenbogen K.A., Clemo H.F., Stambler B.S., Wood M.A., and VanderLugt J.T. Efficacy of ibutilide for termination of atrial fibrillation and flutter. Am J Cardiol 78 (1996) 42-45
4. Kalus J.S., Spencer A.P., Tsikouris J.P., et al. Impact of prophylactic i.v. magnesium on the efficacy of ibutilide for conversion of atrial fibrillation or flutter. Am J Health Syst Pharm 60 (2003) 2308-2312
5. Tercius A.J., Kluger J., Coleman C.I., and White C.M. Intravenous magnesium sulfate enhances the ability of intravenous ibutilide to successfully convert atrial fibrillation or flutter. Pacing Clin Elektrophysiol 30 (2007) 1331-1335
6. Saoudi N., Cosio F., Waldo A., et al. A classification of atrial flutter and regular atrial tachycardia according to electrophysiological mechanisms and anatomical bases. Eur Heart J 22 (2001) 1162-1182
7. Ricard P., Imianitoff M., Yaïci K., et al. Atypical atrial flutters. Europace 4 (2002) 229-239
8. Kalman J.M., Olgin J.E., Saxon L.A., Lee R.J., Scheinman M.M., and Lesh M.D. Electrocardiographic and elektrophysiologic characterization of atypical atrial flutter in man: use of activation and entrainment mapping and implications for catheter ablation. J Cardiovasc Electrophysiol 8 (1997) 121-144
9. Rasmussen H.S., and Thomsen P.E. The electrophysiological effects of intravenous magnesium on human sinus node, atrioventricular node, atrium, and ventricle. Clin Cardiol. 12 (1989) 85-90
10. DiCarlo Jr. L.A., Morady F., de Buitleir M., Krol R.B., Schurig L., and Annesley T.M. Effects of magnesium sulfate on cardiac conduction and refractoriness in humans. J Am Coll Cardiol. 7 (1986) 1356-1362
11. Henyan N.N., Gillespie E.L., White C.M., Kluger J., and Coleman C.L. Impact of intravenous magnesium on post-cardiothoracic surgery atrial fibrillation and length of hospital stay: a meta-analysis. Ann Thorac Surgery 80 (2005) 2402-2406
12. Gullestad L., Birkeland K., Molstad P., Hoyer M.M., Vanberg P., and Kjekshus J. The effect of magnesium versus verapamil on supraventricular arrhythmias. Clin Cardiol. 16 (1993) 429-434
13. Chiladakis J.A., Stathopoulos C., Davlouros P., and Manolis A.S. Intravenous magnesium sulfate versus diltiazem in paroxysmal atrial fibrillation. Int J Cardiol. 79 (2001) 287-291
14. Valentin-Ranc C., and Carier M.F. Evidence for the direct interaction between tightly bound divalent metal ion and ATP on actin. J Biol Chem 289 (1989) 20871-20880
15. Alvarez R., and Bruno J.J. Activation of cardiac adenylate cyclase: hormonal modification of the magnesium ion requirement. Proc Natl Acad Sci USA 74 (1977) 92-95
16. White R.E., and Hartzell H.C. Effects of intracellular free magnesium on calcium current in isolated myocites. Science 239 (1988) 778-780
17. Chiese M., and Inesi G. Mg++ and Mn++ modulation of Ca++ transport and ATPase activity in sarcoplasmatic reticulum vesicles. Arch Biochem Biophys 208 (1981) 586-592
18. Hartzell H.C., and White R.E. Effects of magnesium on inactivation of the voltage-gated calcium current in cardiac myocytes. J Gen Physiol 94 (1989) 745-746
19. White R.E., and Hartzell H.C. Magnesium ions in cardiac function. Regulator of ion channels and second messengers. Biochem Pharmacol 38 (1989) 859-867
20. Vos M.A., Golitsyn S.R., Stangl K., et al. Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. Heart 79 (1998) 568-575
21. Eidher U., Freihoff F., Kaltenbrunner W., and Steinbach K. Efficacy and safety of ibutilide for the conversion of monomorphic atrial tachycardia. Pacing Clin Electrophysiol 29 (2006) 358-362
22. Waldo A.L. Atrial flutter: mechanisms, clinical features, and management. In: Zipes D.P., and Jalife J. (Eds). Cardiac electrophysiology. From cell to bedside (1995), WB Saunders, Philadelphia, PA 666-681
23. Stiles M.K., Sanders P., Disney W., et al. Differential effects of intravenous magnesium on atrioventricular node conduction in supraventricular tachycardia. Am J Cardiol 100 (2007) 1249-1253
24. Caron M.F., Kluger J., Tsikouris J.P., Ritvo A., Kalus J.S., and White C.M. Effects of intravenous magnesium sulfate on the QT interval in patients receiving ibutilide. Pharmacotherapy 23 (2003) 296-300
25. Vester E.G. Clinico-electrophysiologic effects of magnesium, especially in supraventricular tachycardia. Herz 22 Suppl 1 (1997) 40-50
26. White C.M., Xie J., Chow M.S., and Kluger J. Prophylactic magnesium to decrease the arrhythmogenic potential of class III antiarrhythmic agents in a rabbit model. Pharmacotherapy 19 (1999) 635-640
27. Coats A.J. Ethical authorship and publishing. Int J Cardiol 131 (2009) 149-150